SUMMARY The hypertensive and natriuretic effects of chronic administration of adrenocorticotrophic hormone (ACTH) cannot be duplicated by the administration of glucocorticoids and/or mineralocorticoids. We investigated the effects of a fragment of this hormone (ACTH pressor and cardioaccelerator actions sympathetic nervous system R ECENT evidence from our laboratories suggests that it is possible for a single substance to regulate renal sodium excretion (a natriuretic hormone [NH] ) and have cardiovascular effects. 1 ' 2 Investigators searching for a NH have isolated alpha-melanocyte-stimulating hormone (aMSH) and a fragment of adrenocorticotrophic hormone (ACTH 1 " 13 ) from pituitaries 3 based on their natriuretic activity 4 and on affect of salt loading on pituitary aMSH. 4 Another pituitary peptide with natriuretic activity is /3MSH, 5 now thought to be a product of beta-lipotrophin (/3LPH). Schreiberet al. 6 have shown that ACTH 1 -24 is natriuretic. Other investigators 7 " 10 have produced hypertension by chronic administration of ACTH, although the underlying hypothesis in their work is that the hormone was working through an adrenocortical mechanism. Since natriuretic and pressor activities have been attributed to an NH, we hypothesized that all of these properties might be found in a small fragment of ACTH or /3LPH. We therefore investigated the biological activity of the amino acid sequence common to all of these peptides, Met-Glu-His-Phe-ArgTrp-Gly; ACTH-aMSH 4 -10 //3LPH. 47 -" This peptide has previously attracted much attention due to its behavior-modifying properties"" 13 and its ability to improve neuromuscular performance.
14 -' 7 We now report the natriuretic and cardiovascular effects of ACTH Methods and Materials ACTH 4 -10 or (D-Phe 7 ) ACTH 4 -10 (Bachem, Inc., Torrance, California) was dissolved in 75 mM saline at a concentration of 10~3 M, and the pH adjusted to 7 with NaH 2 PO 4 . Peptide solutions were made fresh daily, since in our hands degradation and loss of biological activity occurred in 1 to 3 days in frozen solutions even when they were acidic. The purity of the peptides was ascertained by reverse-phase high performance liquid chromatography (HPLC) with the use of a 10% to 40% propanol gradient in 0.5 M pyridine-formate, pH 3. Fresh peptide solutions yielded a single fluorescamine-positive peak upon chromatography, while solutions over 48 hours old had multiple fluorescamine-positive peaks. Control injections of "nonsense-peptides" containing similar amino acids (e.g., GluArg-Trp-His and Arg-Glu-Trp-His) at doses of 1 to 1000 nmol/kg were used to establish the specificity of responses to ACTH 4 -10 . The rat natriuresis bioassay preparation has been previously described, 1819 Male Sprague Dawley rats weighing 140-160 g were anesthetized with pentobarbital, 50 mg/kg intraperitoneally. The femoral vein was cannulated with PE 50 tubing, the bladder catheterized suprapubically with PE 160, and the trachea cannulated with PE 240 tubing. The animals were placed on a heated pad, and their rectal temperatures were maintained at 37° to 39° C. A 75 mM saline/ pentobarbital solution was infused intravenously at 100 /xl/min throughout the entire assay procedure. To maintain a steady state of anesthesia, a protocol was used that employed increasing rates of pentobarbital infusion. The initial rate at the completion of surgery was 0.12 mg-g BW"'-min"'. The dose was changed to 0.35 mg-g BW"'-min-' at 100 minutes after induction of anesthesia and again to 0.40 mg-g BW-'-min" 1 at 380 minutes after induction of anesthesia. We have found this preparation to give a remarkably stable baseline sodium excretion approximately 2 hours after induction of anesthesia, which remains constant for up to 4 to 5 hours. ACTH 4 
"
10 or nonsense-peptides were administered as a bolus injection (i.v.) in 0.7 ml of 75 mM saline. Urine was collected in graduated containers at 10-or 20-minute intervals, its volume recorded, and Na and K concentrations determined by flame photometry. ACTH 4 
10 or the nonsense-peptides were dissolved in 0.7 ml 75 mM saline and given as a bolus injection over a 5-minute period in place of the anesthesia solution, or dissolved in the anesthetic solution and given as a infusion for 150 minutes. Changes in U Na V from baseline were tested at 10-or 20-minute intervals for statistical significance by the multiple comparison test of Dunnett, or the cumulative sodium excretion for 130 minutes was analyzed by Duncan's new multiple range test. Above a minimally active dose, the bolus injections or infusions produced similar effects on sodium excretion. Thus, the data from these active doses were pooled. , or nonsense-peptides were assessed in anesthetized or unanesthetized rat preparations. The former bioassay preparation was similar to that described for natriuresis. In addition, arterial blood pressure was monitored via a femoral catheter connected to a pressure transducer and a Grass Polygraph recorder. A ganglionic blocker (mecamylamine, 10 mg/kg) was administered to achieve a steady baseline blood pressure, as well as to rule out direct central sympathetic nervous system effects of the peptides. ACTH 4 -10 or the nonsense-peptides were dissolved in 50 fi\ of 75 mM saline and administered as a bolus injection.
For the second cardiovascular assay preparation, 7-week-old male Sprague-Dawley rats were immobilized by the administration of ketamine (150 mg/kg, i,p.). Arterial catheters (PE 60) were implanted into the ascending aorta via the left carotid artery, and venous catheters (PE 50) were implanted into the right jugular vein. Both the arterial and venous catheter tips were made of silicone rubber tubing (Silastic, DowCorning, Midland, Michigan; 0.012 in. i.d. x 0.025 in. o.d.) and drawn over the outside wall of the PE tubing. The catheters were then passed under the skin and exteriorized to the back of the neck via a small incision. They were cut to approximately 4 cm in length and sealed with stainless steel stilettes. The animals were allowed to recover for at least 72 hours after surgery.
Individual rats were placed in a lucite cage (30 x 30 x 30 cm). The exteriorized arterial catheter was fitted to a swivel cannula that was attached to a low-volume displacement transducer (Electromedics, MS 20, Eagle wood, Colorado) secured above the cage to measure arterial blood pressure. Zero pressure was referenced to midchest level. Heart rate (HR) was electronically derived from the arterial pulse signal. Recordings were made on a Brush 8-channel recorder (Model 280, Cleveland, Ohio). Rats were acclimated in the cage for at least 30 minutes, after which control recordings were made for another 15 minutes. ACTH 4 -10 and (D-Phe^) ACTH 4 " 10 were administered as an i.v. bolus dose in normal saline (100 /Ltl-100 g BW- 1 ). Phentolamine (1.0 mg/kg, i.v.) was used to block areceptors, while metoprolol (1.0 mg/kg, i. v.) was used to block /3-receptors. Norepinephrine (1.0 Mg/kg) and isoproterenol (0.5 /ig/kg) were used to test the efficacy of the a-and /3-blockade, respectively. Each agonist was administered 30 minutes before and 15 minutes after the respective receptor antagonist to ensure antagonism before the administration of (D-Phe 7 ) ACTH.
Bilateral adrenalectomy was performed in five rats that had previously been implanted with chronic indwelling arterial and venous catheters. The rats were anesthetized with ether, and the adrenal glands were removed through a dorsal (retroperitoneal) incision. Animals were allowed to recover for 24 hours during which time they were given saline 150 mM solution and food ad libitum.
Results
Vehicle control experiments showed only a small, transient, insignificant increase in U NB V during the first 30 minutes after injection (Figure 1 C) . Bolus injections of 7-35 nmol/kg ACTH 4 -10 in 12 rats caused a progressive increase in U Nl V from baseline of 4.1 ± 0.34 /u.Eq/min to a peak of 5.4 ± 0.46 ^.Eq/min at 50 to 70 minutes after the injection (Figure 1 A) . The increment for a single 10-or 20-minute collection period was not significantly different from the control. However, cumulative U Nl V for the 130 minutes of the assay after ACTH 4 -10 was significantly (p < 0.05) elevated to 129 ± 40 /i.Eq/130 minutes compared to 0.25 ± 38 /j.Eq/130 minutes in rats given vehicle control. Injections of nonsense peptides caused no changes in U N ,V above that seen with vehicle control. A constant infusion of 175 to 350 pmol/kg/min of ACTH 4 -10 in 13 rats raised U No V from a baseline of 4.5 ± 0.31 /^.Eq/min to a level of about 6.1 within 30 to 50 minutes after the beginning of the infusion. This rate of U Na V was maintained fairly constant during the infusion period (Figure 1 B) . Cumulative U Na V during the constant infusion was 154 ± 39 yuEq/130 minutes (p < 0.05 compared to vehicle control). The difference between cumulative U Nn V in the bolus injection experiments and the constant infusion experiments was not statistically significant (p > 0.1). No significant natnuretic response was observed with an ACTH 4 -10 infusion of 70 pmol/kg/min. Initially, the pressor effects of ACTH 4 "
10 were evaluated in the anesthetized rat preparation. Each rat was allowed to stabilize for at least 40 minutes after mecamylamine, and the mean blood pressure did not differ by more than ±5% for 20 minutes prior to an injection. Figure 2 depicts the blood pressure increase seen after injection of 700 nmol/kg and 1.7 yu,mol/kg of ACTH 4 " 10 . The average increase in mean arterial blood pressure (MAP) for a 700 nmol/kg injection was 15 ± 5 mm Hg, while for 1.7 ^.mol/kg it was 32 ± 8 mm Hg (n = 5 for both doses). The smallest dose required to give a significant pressor response was 50 nmol/kg. Injection of nonsense peptides (n = 5) produced no change in blood pressure.
It is well known that anesthetized bioassay preparations may not always give results that are identical to those observed in conscious, unrestrained animals. We therefore repeated and extended our studies with ACTH 4 (Figures 3 and 4) .
The rise in MAP, but not HR, was significantly reduced by pretreatment with the a-antagonist phentolamine (Table 1) . Similarly, the rise in HR, but not MAP, was significantly reduced by pretreatment with the selective /3,-antagonist metoprolol (Table 1) After adrenalectomy, the same dose of the peptide increased MAP by 36 ± 1.3 mm Hg and increased HR by 54 ± 5.4 bpm. Control MAP before and after adrenalectomy was not significantly different. However, control HR after adrenalectomy increased by 89 ± 9.5 bpm.
Discussion ACTH-induced blood pressure elevations have been reported in a number of species, 7 " 9 including humans. 10 In almost all of these reports the blood pressure effects have been suggested to result from adrenocortical stimulation, even though a consistent correlation between increased circulating levels of a specific adrenal steroid and blood pressure was not demonstrated. In addition, in at least one report the renin-angiotensin system was found to be normal or suppressed in states of high circulating ACTH. 8 Recently, Lohmeier and Carroll 20 extensively investigated the chronic effects of ACTH administration on blood pressure and suggested that the hypertensive effects might be due to increased secretion of an unknown pressor factor. Attempts to totally duplicate the hypertensive effects of ACTH infusions by glucocorticoid and/or mineralocorticoid in- fusions were not successful. No one has previously suggested that the hypertensive effects of ACTH might be directly due to an extraadrenal effect of this hormone. However, support for this hypothesis is found in clinical studies that show a high incidence (>75%) of hypertension associated with the natural course of Cushing's disease, 21 while the incidence of hypertension in steroid-treated patients is between 5% 22 and
The delayed pattern of natriuresis observed with bolus injections of ACTH 4 -10 (peak effect at 40-80 minutes) is similar to the effect of aMSH in the rat. Orias and McCann 24 reported that bolus injections of aMSH produced a natriuretic effect that plateaued at 40 to 80 minutes postinjection. These natriuretic patterns are similar to those seen with extracts prepared from plasma of saline-expanded dogs, 1819 but are slightly different in that the peak of natriuresis occurred about 20 minutes later than that of plasma extracts.
It is difficult to compare the dose relationship between ACTH 4 -10 and ACTH or aMSH with regard to the renal and cardiovascular effects due to the different assays used, the approaches to data analysis, and the routes of administration. For example, the natriuretic effects of ACTH 6 and aMSH 24 in rats have usually been demonstrated with bolus injections, while the pressor actions are always shown by infusions. However, our work indicates that with bolus injections of ACTH 4 " 10 , natriuresis occurs at l/35th the dose needed to induce a significant pressor effect. This dose-dependent relationship is similar to the findings of Lohmeier and co-workers, 20 u who showed that subpressor infusions of ACTH in dogs induced a significant natriuresis.
The bolus injections of ACTH 1 -24 (i.v.) or aMSH (i.p.) used to produce a significant natriuretic effect in rats vary from 16.5 nmol (ACTH 1 -24 ) to 30 nmol (aMSH). 6 24 These doses, respectively, produced cumulative sodium excretions of approximately 125 /j.Eq/5 hr and 165 /uEq/100 min. In comparison, a 7 to 35 nmol/kg bolus of ACTH 4 -10 produced a net sodium excretion of 129 ^iEq/130 min. While one might infer that ACTH 4 -10 is more potent than ACTH 1 -24 or aMSH, this difference in natriuretic activity was most likely due to the use of different bioassay approaches.
The ability of a-and /3-receptor antagonists to reduce the pressor and cardioaccelerator effects of (DPhe 7 ) ACTH 4 " 10 suggests that catecholamines play a role in its action. There is the possibility that some of the cardiovascular effects occur through a central-nervous-system-induced action. However, the use of ganglionic blocked rats for the pressor studies and the rapidity of onset of these effects strongly indicate that there is a major peripheral component to the action of ACTH 4 10 sequence has been described. 29 The presumed physiological ligand for these receptors is yMSH. This is a recently described fragment of proopiocortin, 30 which contains an amino acid sequence analagous to ACTH 4 -10 (Met-Gly-His-Phe-Arg-TrpAsp). The yMSH receptor is not the classic MSH receptor since -yMSH has only a fraction of the biological activity of aMSH in a melanophore assay. 31 However, -yMSH is two to three times more powerful than ACTH or aMSH for competition at this new class of receptors. 29 Zeiler et al. 32 showed that ACTH-induced potentiation of norepinephrine inotropism in canine atrial muscle was associated with specific binding of ACTH to the tissue. We have found that -yMSH-containing peptides (such as y 2 MSH, a didecapeptide) are 10 to 100 times more potent than ACTH 4 " 10 in cardiovascular and natriuresis studies (unpublished observations).
Placing aside consideration of the physiological significance of the ACTH 4 "
10 sequence, we believe our data clearly demonstrate a peptide that is natriuretic and has catecholamine-dependent cardiovascular effects. We have previously proposed 33 in our work with a natriuretic factor and a volume-expansion-released pressor factor that NH-like compounds might well have cardiovascular effects at substantially higher doses than those needed for natriuresis. These properties can be demonstrated in this fragment.
In conclusion, the identification of a natriuretic and hypertensive fragment of ACTH provides a unique explanation for the renal and cardiovascular effects seen with chronic ACTH administration. The development of ACTH 4 -10 analogs with enhanced peripheral actions may be the forerunners of a new class of drugs that regulate the renal and cardiovascular systems.
